Since its founding in 1996, Medison has brought a true promise of innovation to patients suffering from severe and rare diseases.
Medison established a unique global platform designed to address one of today’s most significant healthcare challenges. Even today, at a time of remarkable scientific breakthroughs, many patients around the world living with severe and rare conditions still do not receive appropriate or timely medical care.
Medison is working to change this reality by creating a new category in healthcare. Operating in markets outside the U.S., Japan, and Western Europe, Medison enables biotech companies to reach patients worldwide quickly and efficiently through its unique global platform—delivering advanced and timely medical solutions to patients who previously had no adequate access. Together with biotech partners, we reach more patients, faster, driven by the belief that every person, regardless of geographic location, deserves the best possible medical care.
This same commitment to equity in access to medical treatment guides our work in Israel. Every day, we strive to ensure that every patient has the opportunity to receive groundbreaking therapies that can change the course of their lives.
For this reason, our collaboration with Haverim L’Refuah—and the shared values we uphold—is of great importance to us. I would like to thank Haverim L’Refuah and Baruch Liberman, it's leader, for our meaningful joint efforts.
Meir Jacobson
Founder & CEO
